American Century Companies Inc. Has $91.85 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

American Century Companies Inc. boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 14.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,274,067 shares of the medical equipment provider’s stock after purchasing an additional 157,731 shares during the period. American Century Companies Inc.’s holdings in Hologic were worth $91,848,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. General Partner Inc. bought a new stake in shares of Hologic during the fourth quarter worth $26,000. Venturi Wealth Management LLC lifted its position in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 159 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

HOLX has been the topic of several research analyst reports. Stephens reissued an “overweight” rating and set a $84.00 price target on shares of Hologic in a research note on Thursday, February 6th. Wolfe Research started coverage on Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating on the stock. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Hologic has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Stock Up 0.7 %

Shares of NASDAQ HOLX opened at $61.89 on Tuesday. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock has a market cap of $13.89 billion, a P/E ratio of 19.52, a P/E/G ratio of 2.14 and a beta of 0.97. The firm has a 50 day moving average price of $65.89 and a 200 day moving average price of $73.81.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.